Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.The Pan African Medical Journal|June 22, 2019
Severe odontogenic infections: a 5-year review of a major referral hospital in GhanaPaa-Kwesi Blankson, Grace Parkins, Matthew Owusu Boamah, et al.Journal of Clinical Psychopharmacology|February 21, 2013
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trialsSrihari Gopal, David Hough, Keith Karcher, et al.Neuropsychiatric Disease and Treatment|July 2, 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized StudiesMaju Mathews, Srihari Gopal, Arun Singh, et al.Neuropsychiatric Disease and Treatment|January 27, 2016
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled studyHongyan Zhang, Huafang Li, Yanning Liu, et al.BMC Psychiatry|March 30, 2012
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaDanielle Coppola, Yanning Liu, Srihari Gopal, et al.The International Journal of Neuropsychopharmacology|February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.Neuropsychiatric Disease and Treatment|June 14, 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophreniaMaju Mathews, Srihari Gopal, Isaac Nuamah, et al.Journal of Clinical Pharmacology|July 21, 2015
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyPaulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.The Journal of Rheumatology|October 3, 2006
Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritisMichael H Weisman, Patrick Durez, David Hallegua, et al.Pageof 5